🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Split 2:1 del 22/11/1999

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.656.089

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
27,17 (puede no estar actualizado)
Dividend yield
2,31% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 3 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/10/2013 112,42 114,85 112,35 114,28 +2,55% 2,22% 3.541.600
15/10/2013 111,62 112,12 110,89 111,44 -0,13% 1,10% 1.968.900
14/10/2013 110,02 111,69 109,59 111,58 +0,62% 1,91% 2.211.100
11/10/2013 110,00 111,51 109,66 110,89 +0,88% 1,68% 2.431.300
10/10/2013 107,17 109,99 106,99 109,92 +3,42% 2,80% 3.096.600
09/10/2013 108,13 108,42 105,76 106,28 -1,37% 2,46% 5.440.700
08/10/2013 110,17 110,80 106,91 107,76 -2,23% 3,53% 4.244.200
07/10/2013 111,47 111,71 110,08 110,22 -2,38% 1,46% 2.662.300
04/10/2013 110,74 113,49 110,11 112,91 +1,61% 3,05% 3.088.000
03/10/2013 112,99 113,06 110,07 111,12 -1,72% 2,65% 3.058.800
02/10/2013 113,88 113,88 112,40 113,06 -1,33% 1,30% 2.472.000
01/10/2013 111,99 114,61 111,74 114,58 +2,38% 2,56% 2.822.600
30/09/2013 112,08 113,27 111,50 111,92 -1,12% 1,58% 3.041.300
27/09/2013 112,43 114,27 112,17 113,19 +0,30% 1,87% 1.940.200
26/09/2013 113,63 114,08 112,55 112,85 +0,33% 1,35% 3.534.600
25/09/2013 114,80 114,80 112,40 112,48 -2,00% 2,09% 3.651.700
24/09/2013 115,19 116,48 114,59 114,78 -0,23% 1,64% 2.225.700
23/09/2013 115,89 116,50 115,03 115,05 -1,54% 1,27% 2.518.800
20/09/2013 117,15 117,61 116,07 116,85 -0,28% 1,31% 5.324.700
19/09/2013 117,85 117,85 115,66 117,18 -0,29% 1,86% 3.030.400
18/09/2013 115,59 117,91 115,01 117,52 +1,55% 2,51% 2.609.400
17/09/2013 117,30 117,30 115,33 115,73 -1,24% 1,68% 3.145.200
16/09/2013 116,21 117,18 115,41 117,18 +1,84% 1,52% 4.710.700
13/09/2013 113,97 115,22 113,27 115,06 +1,41% 1,71% 3.297.100
12/09/2013 112,22 113,68 111,96 113,46 +1,33% 1,53% 2.685.800
11/09/2013 112,23 112,89 111,38 111,97 +0,73% 1,35% 3.196.200
10/09/2013 112,32 112,60 110,42 111,16 -0,46% 1,94% 3.139.700
09/09/2013 111,34 111,96 110,46 111,67 +0,59% 1,35% 2.826.800
06/09/2013 113,04 113,04 109,99 111,01 -1,70% 2,70% 3.028.400
05/09/2013 112,89 113,28 111,81 112,93 -0,08% 1,30% 2.710.500